Trials / Active Not Recruiting
Active Not RecruitingNCT03199300
Investigating Cardiovascular Adverse Events Related to Cancer Treatment
Investigating Cardiovascular Adverse Events Related to Cancer Treatment: a Study of Extreme Toxicity Using Induced Pluripotent Stem Cells
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown. Unraveling extreme cardiovascular toxic responses in cancer patients may help understand the pathophysiology of cardiovascular toxicity of these agents and help in understanding the more subtle, long-term cardiovascular side effects that affect a larger part of cancer survivors. With induced pluripotent stem cells we will obtain patient-derived cells to recapitulate and mimic and study pathological (cardiovascular) responses and (cardiovascular) toxicity in vitro.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anthracyclines | Chemotherapy regimen containing anthracyclines. |
| DRUG | Trastuzumab | Systemic treatment including trastuzumab. |
| DRUG | Cisplatin | Chemotherapy including cisplatin. |
| DRUG | Bleomycin | Chemotherapy including bleomycin. |
Timeline
- Start date
- 2017-12-12
- Primary completion
- 2025-02-06
- Completion
- 2027-01-01
- First posted
- 2017-06-26
- Last updated
- 2025-12-11
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03199300. Inclusion in this directory is not an endorsement.